Sarah Jurmeister

Transcriptomic analysis reveals inhibition of androgen receptor activity by AMPK in prostate cancer cells

D. Neal, L. Fryer, A. Ramos-Montoya, 2014, Oncotarget.

A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer

F. Baltazar, C. Lopes, J. Attig, 2014, BMC Cancer.

Downregulation of androgen receptor transcription by promoter g-quadruplex stabilization as a potential alternative treatment for castrate-resistant prostate cancer.

Stephan A. Ohnmacht, S. Balasubramanian, M. Micco, 2013, Biochemistry.

HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network

S. Vowler, I. Mills, D. Neal, 2014, EMBO molecular medicine.

Identification of potential therapeutic targets in prostate cancer through a cross‐species approach

M. Dunning, D. Neal, J. Carroll, 2018, EMBO molecular medicine.

A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy

D. Neal, L. Fryer, F. Baltazar, 2015, The Journal of pathology.

MicroRNA-200c Represses Migration and Invasion of Breast Cancer Cells by Targeting Actin-Regulatory Proteins FHOD1 and PPM1F

Stefan Wiemann, I. Keklikoglou, Ö. Sahin, 2011, Molecular and Cellular Biology.

Abstract A123: Preclinical evaluation of dual mTOR inhibitor, AZD2014, in prostate cancer

D. Neal, J. Griffiths, B. Davies, 2015 .